← All sources
Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference
Prospective wearable cohort (n=66 adults initiating GLP-1 RAs vs propensity-matched controls): ~10% weight loss at 12 weeks with +3.2 bpm resting heart rate; authors report ~6 ms HRV reduction statistically mediating RHR increase; exploratory trends link higher weekly activity with smaller RHR rises.
Design
- Population: 66 adults (mean age 42 ± 9 y, BMI 30.0 ± 7 kg/m²) beginning GLP-1 receptor agonist therapy; tracked from 1 week before through 12 weeks after initiation (WHOOP metrics)
- Comparator: propensity-score–matched users from a larger wearable database with similar baseline traits (abstract: matched variables P > 0.26)
- Readouts: resting heart rate (RHR), heart rate variability (HRV), physical activity volume, sleep
Main outcomes vs matched control (12 weeks; abstract)
- Body weight: −10.0% (95% CI −11.2% to −8.5%; P < 0.05)
- RHR: +3.2 ± 0.8 bpm (P < 0.05)
- HRV: −6.2 ± 1.4 ms; authors report HRV change statistically mediates the RHR increase (P < 0.01 for mediation pathway)
- Physical activity: trends (P < 0.10) for +31.5 ± 13.2 min/week with GLP-1 initiation and for higher activity attenuating RHR increases—hypothesis-generating only
Evidence hygiene
- Observational initiation study with matching, not an RCT—residual confounding possible
- Molecule-agnostic cohort; do not read autonomic shifts as molecule-specific regulatory claims
- Telemetry window (12 weeks) complements, but does not replace, cardiovascular outcome trials for prescriber decisions
Outcomes
- Mean body-weight change −10.0% (95% CI −11.2% to −8.5%; P < 0.05 vs matched controls).
- Resting Heart Rate3.2bpm (Beats Per Minute)
- Heart Rate Variability-6.2ms (RMSSD)
- Trend (P < 0.10): +31.5 ± 13.2 min/week activity; higher activity may blunt GLP-1–associated RHR increases—requires confirmation.